Dr Anil K Vithala, MD | |
477 Connecticut Blvd, Suite 112, East Hartford, CT 06108-3268 | |
(860) 289-0623 | |
Not Available |
Full Name | Dr Anil K Vithala |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 477 Connecticut Blvd, East Hartford, Connecticut |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083601256 | NPI | - | NPPES |
010034801CT01 | Other | CT | ANTHEM |
01034801 | Other | CIGNA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 034801 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Anil K Vithala, MD 477 Connecticut Blvd, Suite 112, East Hartford, CT 06108-3268 Ph: (860) 289-0623 | Dr Anil K Vithala, MD 477 Connecticut Blvd, Suite 112, East Hartford, CT 06108-3268 Ph: (860) 289-0623 |
News Archive
Xenon today announced a strategic alliance with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain.
Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial.
Few Americans know what a "medical loss ratio" is, but a fierce struggle over how to calculate it under the new health care reform law will determine how much insurers must spend on patient care and how much they can retain for administration and profits. This is but one of many battles that will emerge as federal and state regulators develop regulations to implement reform (5/23).
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
› Verified 8 days ago
Mrs. Vivien A Iloeje, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 94 Connecticut Blvd, East Hartford, CT 06108 Phone: 860-528-1359 Fax: 860-290-4142 | |
Dr. Sukhwant Singh Sethi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 477 Connecticut Blvd, 304, East Hartford, CT 06108 Phone: 860-289-9376 | |
Dr. Lillian Overman, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 144 Main St, East Hartford, CT 06118 Phone: 860-918-0069 | |
Niko Broodie-murray, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Connecticut Blvd, East Hartford, CT 06108 Phone: 860-282-3894 Fax: 860-282-8582 | |
Jorge L. Diez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 893 Main St Ste 202, East Hartford, CT 06108 Phone: 860-247-2137 Fax: 860-728-0480 | |
Dr. Fielding Johnson Iii, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 893 Main St Ste 202, East Hartford, CT 06108 Phone: 860-528-4124 Fax: 860-282-1213 |